Groundbreaking study in squamous cell lung cancer opens at more than a hundred and fifty new locations
The Lung-MAP trial, a multi-drug, multi-sub-study, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer, that launched on June 16th 2014, today announced that it has expanded to an additional 169 locations throughout the United States. They join 85 locations that have been participating in the trial since the June launch. All locations can be found here: http://www.lung-map.org/locations
The Lung-MAP study, formally known as SWOG S1400, uses genomic profiling to match patients to one of several different sub-studies testing investigational treatments that target the genomic alterations found to be driving the growth of their cancer. This innovative approach to clinical testing should both speed access to investigational new drugs for patients and ease the significant recruitment and infrastructure burdens on researchers involved in traditional clinical trials.
The trial is currently testing five experimental drugs—four targeted therapies and an anti-PD-L1 immunotherapy. It is expected to screen as many as 1250 patients each year for over 200 cancer-related genomic alterations. The results of this screening will be used to assign each patient to the trial sub-study that is testing a drug best matched to their tumor’s genomic profile.
Lung-MAP is a unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), Foundation Medicine, and leading cancer and lung cancer patient advocacy organizations (a full list is at http://www.lung-map.org/about/partners).
The trial will continue to expand over the coming months, and will ultimately be conducted at hundreds of centers across the country by NCI’s National Clinical Trials Network, led by SWOG, and partly funded by NCI through its Cancer Therapy Evaluation Program. Significant additional funding will be provided by the participating companies as part of a partnership managed by FNIH that also involves the Food and Drug Administration (FDA), Friends, and other patient advocacy organizations. The trial infrastructure is capable of testing as many as 5-7 additional drugs over the next 5 years.
Co-principal investigators on Lung-MAP include Vali Papadimitrakopoulou, Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center; David Gandara, Chair, Lung Committee, SWOG and Director, Thoracic Oncology Program at UC Davis Cancer Center; Roy Herbst, Ensign Professor of Medicine and Chief of Medical Oncology at Yale Cancer Center; Mary Redman, Ph.D., Associate Member, Fred Hutchinson Cancer Research Center; and Fred R. Hirsch, M.D., Ph.D., Professor of Medicine and Pathology & Associate Director for International Programs at the University of Colorado Cancer Center.
For more information please visit the Lung-MAP Website: www.Lung-MAP.org
ClinicalTrials.gov Entry Page: https://clinicaltrials.gov/ct2/show/NCT02154490?term=1400&recr=Open&rank=4
Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – email@example.com or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – firstname.lastname@example.org